AcouSort AB (ACOU) - Total Assets
Based on the latest financial reports, AcouSort AB (ACOU) holds total assets worth Skr26.52 Million SEK (≈ $2.85 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AcouSort AB - Total Assets Trend (2013–2025)
This chart illustrates how AcouSort AB's total assets have evolved over time, based on quarterly financial data. Also see AcouSort AB (ACOU) total market value for the company's overall valuation and market capitalisation.
AcouSort AB - Asset Composition Analysis
Current Asset Composition (December 2025)
AcouSort AB's total assets of Skr26.52 Million consist of 72.9% current assets and 27.1% non-current assets. Review ACOU total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 35.2% |
| Accounts Receivable | Skr434.00K | 2.4% |
| Inventory | Skr2.56 Million | 14.3% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr4.84 Million | 27.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how AcouSort AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ACOU stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AcouSort AB's current assets represent 72.9% of total assets in 2025, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 35.2% of total assets in 2025, down from 87.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 27.1% of total assets.
AcouSort AB Competitors by Total Assets
Key competitors of AcouSort AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
AcouSort AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.69 | 1.03 | 1.21 |
| Quick Ratio | 1.49 | 0.67 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr8.77 Million | Skr214.00K | Skr1.12 Million |
AcouSort AB - Advanced Valuation Insights
This section examines the relationship between AcouSort AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.32 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 45.2% |
| Total Assets | Skr17.89 Million |
| Market Capitalization | $6.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values AcouSort AB's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: AcouSort AB's assets grew by 45.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for AcouSort AB (2013–2025)
The table below shows the annual total assets of AcouSort AB from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr17.89 Million ≈ $1.93 Million |
+45.19% |
| 2024-12-31 | Skr12.32 Million ≈ $1.33 Million |
-64.29% |
| 2023-12-31 | Skr34.51 Million ≈ $3.71 Million |
-19.09% |
| 2022-12-31 | Skr42.66 Million ≈ $4.59 Million |
+16.67% |
| 2021-12-31 | Skr36.56 Million ≈ $3.93 Million |
+177.58% |
| 2020-12-31 | Skr13.17 Million ≈ $1.42 Million |
+63.92% |
| 2019-12-31 | Skr8.04 Million ≈ $864.69K |
-53.93% |
| 2018-12-31 | Skr17.44 Million ≈ $1.88 Million |
+252.52% |
| 2017-12-31 | Skr4.95 Million ≈ $532.38K |
-58.91% |
| 2016-12-31 | Skr12.04 Million ≈ $1.30 Million |
+4517.90% |
| 2015-12-31 | Skr260.70K ≈ $28.06K |
-71.67% |
| 2014-12-31 | Skr920.08K ≈ $99.02K |
-61.88% |
| 2013-12-31 | Skr2.41 Million ≈ $259.72K |
-- |
About AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, a module that enables in-line analysis of blood plasma from whole blood samples; Acous… Read more